- Home
- ARW vs PTGX Comparison
ARW vs PTGX Comparison
Compare ARW & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARW | PTGX |
|---|---|---|
| Founded | 1935 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ARW | PTGX |
|---|---|---|
| Price | $111.25 | $85.70 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $102.00 | $90.56 |
| AVG Volume (30 Days) | 471.1K | ★ 994.3K |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 9.05 | 0.72 |
| Revenue | ★ $29,389,382,000.00 | $209,217,000.00 |
| Revenue This Year | $9.50 | N/A |
| Revenue Next Year | $4.23 | $296.47 |
| P/E Ratio | ★ $12.35 | $124.05 |
| Revenue Growth | ★ 3.16 | N/A |
| 52 Week Low | $86.50 | $33.70 |
| 52 Week High | $134.74 | $96.54 |
Technical Indicators
Market Signals| Indicator | ARW | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 47.46 |
| Support Level | $110.34 | $88.30 |
| Resistance Level | $116.94 | $96.54 |
| Average True Range (ATR) | 2.54 | 3.46 |
| MACD | 0.33 | -0.61 |
| Stochastic Oscillator | 40.96 | 18.63 |
Price Performance
Historical ComparisonAbout ARW Arrow Electronics Inc.
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.